Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
Medicamente
Centauri Therapeutics Limited Jul 29 2025 Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri's ABX-01
din zilele anterioare